The Journal of Steroid Biochemistry and Molecular Biology
Volume 58, Issue 2, May 1996, Pages 139-146
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model
References (32)
Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer
Results of a double-blind study
Urology
(1991)- et al.
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
J. Urol.
(1992) - et al.
Prostate and bone fibroblasts induce human prostate cancer growth in vivo; implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis
J. Urol.
(1992) - et al.
Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction
Analyt. Biochem.
(1987) - et al.
Molecular cloning of human prostate specific antigen cDNA
FEBS Lett.
(1987) Clonal adaptation during carcinogenesis
Biochem. Pharmacol.
(1990)Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
J. Urol.
(1991)- et al.
Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
Cancer Res.
(1941) - et al.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
New Engl. J. Med.
(1989) - et al.
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial
Urology
(1993)
Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
J. Urol.
(1993)
Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline
Cancer Res.
(1993)
Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblasts
Cancer Res.
(1991)
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
Cancer Res.
(1992)
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
Cancer Res.
(1990)
Effects of intermittent androgen suppression on androgen-dependent tumors; apoptosis and serum prostate-specific antigen
Cancer
(1993)
Cited by (189)
Deregulated transcription factors and poor clinical outcomes in cancer patients
2022, Seminars in Cancer BiologyThreshold dynamics of a stochastic model of intermittent androgen deprivation therapy for prostate cancer
2021, Communications in Nonlinear Science and Numerical SimulationModeling the synergistic properties of drugs in hormonal treatment for prostate cancer
2021, Journal of Theoretical BiologyRevisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?
2019, European Urology FocusBipolar androgen therapy: an intriguing paradox
2018, The Lancet Oncology
Copyright © 1996 Published by Elsevier Ltd.